Loading...
NPI 1124314653 · Kent, WA · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Yicheng Chen is a ophthalmology physician provider located in Kent, Washington. This profile covers 18 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Yicheng Chen |
| Address | 321 Ramsay Way Ste 107 |
| City | Kent |
| State | WA |
| ZIP | 98032 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | June 23, 2011 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2M |
| Medicaid | $290 |
This provider is effectively Medicare-focused: Total Medicare revenue is $2M compared with Total Medicaid revenue of $293, so Medicare accounts for the overwhelming share of billed revenue. The file-level precomputed measures show the top three Medicare codes account for 83.8% of this provider's total Medicare revenue while the top three Medicaid codes account for 100.0% of the much smaller Medicaid revenue base, underscoring a single-payer concentration.
Clinical/service mix is centered on intravitreal pharmacologic therapy and retina diagnostics. The single largest Medicare line item is J0178 (aflibercept) with $1.3M revenue (64.8% of Medicare revenue), supported by J2777 (faricimab) at $258.7K (13.0%) and the injection procedure 67028 at $120.1K (6.0%), which together indicate a practice model driven by recurrent anti‑VEGF injections and associated retinal procedure visits.
Revenue concentration on Medicare is high and narrowly focused: the precomputed top-3 share of 83.8% means J0178, J2777, and 67028 dominate the Medicare portfolio. Relying primarily on high-volume biologic injections (J0178 $1.3M, J2777 $258.7K) makes overall revenue sensitive to utilization and reimbursement dynamics for intravitreal drugs and related procedural codes.
Although injections drive Medicare dollars, diagnostic imaging is a clear operational emphasis: 92134 appears on both payers and is a notable outlier on Medicare with 1.9K claims, $59.6K revenue, and a national standing of #1116 of 26868 providers (96th percentile; notably above typical national volume for this code). High OCT volume is consistent with active monitoring of macular disease and supports the injection workflow by providing frequent diagnostic follow-up.
Competitive standing is mixed across codes: for the flagship drug J0178 the provider ranks #584 of 3204 providers nationally (82th percentile; typical, unremarkable volume for this code), indicating solid but not dominant national position on aflibercept administration. Other Medicare injection and E/M codes like J2777 (#1063 of 2039, 48th percentile) and 67028 (#1143 of 4255, 73th percentile) are also characterized as typical, unremarkable volume, so the practice is a modest-to-strong regional player rather than a national leader in injection volume.
Medicaid activity is very small in absolute terms and concentrated: the top Medicaid code is 92134 (211 claims, $1 avg paid/claim, $211 revenue), comprising 72.0% of the provider's Medicaid revenue, with 99213 contributing the remaining 28.0% ($82). The precomputed 100.0% top-3 Medicaid share and the $293 total Medicaid revenue indicate the provider is functionally single-payer from a revenue perspective and has limited Medicaid footprint.
State-level competitive standing on Medicaid is modest. For Medicaid 92134 the provider ranks #55 of 100 in-state (45th percentile; typical, unremarkable volume for this code) and 99213 ranks #1530 of 1863 (18th percentile; typical, unremarkable volume), so the provider is not a leading Medicaid participant statewide and Medicaid billing appears ancillary to the core Medicare-driven business.
The provider has an established practice tenure: NPI enumerated on 2011-06-23 (~15 years ago), indicating a sustained presence in the market that aligns with the observed recurring injection and imaging volumes. Combined with the concentrated Medicare revenue base, this suggests a stable retinal/ophthalmology practice that has matured around intravitreal therapy and OCT monitoring.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
18 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,890 | $680 | $1.3M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 9,240 | $30 | $258.7K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,190 | $100 | $120.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,920 | $30 | $59.6K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 210 | $220 | $44.5K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 620 | $70 | $43.6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 420 | $100 | $40.2K |
| J3490 | Unclassified drugs | 20 | $1,960 | $39.2K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 220 | $150 | $32.5K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 240 | $100 | $24.5K |
Showing 1–10 of 18
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 18 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
18 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J2777 | 32 | 50 | 12,780 | $30 | $599.7K |
| J0178 | 17 | 90 | 470 | $680 | $597.2K |
| Q5128 | 12 | 10 | 520 | $220 | $136.6K |
| 67028 | 30 | 110 | 550 | $90 | $72.9K |
| J3490 | 63 | 70 | 70 | $50 | $51.2K |
| J7312 | 11 | 20 | 270 | $160 | $46K |
| 67036 | 22 | 20 | 20 | $1,140 | $28.6K |
| 92014 | 111 | 790 | 110 | $80 | $16.8K |
| J7999 | 35 | 70 | 150 | $70 | $15.9K |
| 99214 | 2,252 | 10,860 | 100 | $80 | $13.6K |
Showing 1–10 of 18
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 210 | $1 | $210 |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 40 | $1 | $80 |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 10 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Washington providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Washington median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,530 | 1,860 | 610 | $40 | $295.5K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 56 | 60 | 710 | $40 | $81.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 55 | 100 | 240 | $10 | $22.2K |
Other providers in the same ZIP code as Yicheng Chen, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.